Onkolytische Sendai-Viren als neuartiger Ansatz zur virotherapeutischen Behandlung des HCC

Introduction: Hepatocellular carcinoma (HCC) is one of the most common cancers. Virotherapy provides an alternative new mechanistic treatment approach, based on a selective viral replication in tumor cells, inducing cellular destruction. To reach a broad range of different tumors and select an ideal vector system for each disease entity, including tumors of hepatobiliary origin, it is challenging to develop new oncolytic viruses with attractive properties. Murine parainfluenza virus type I (Sendai virus, SeV) is a murine pathogen that infects human cell types in a highly efficient manner. SeV has entered clinical trials recently; however, infectious progeny viruses are not constitutively produced in host cells, which mean an immediate abrogation of viral replication in cancer cells.